Skip to content
Open access

Early CMV-specific T cell immune reconstitution after kidney transplantation: A prospective AIM-based cohort study.

Aug 2026 · Transplant Immunology · pp. 102441 · 0 citations · 40 references
Medicine

Abstract

Objectives

Cytomegalovirus (CMV) remains a major cause of morbidity following kidney transplantation (KT). We applied flow cytometry-based phenotyping and activation-induced marker (

Aim

assays to characterize early immune reconstitution and CMV-specific T-cell dynamics after KT and to determine whether early

Aim

responses are associated with clinically significant CMV infection (CS-CMVi).

Methods

Twenty-nine adult KT recipients were followed prospectively for 12 months: 13 donor CMV-positive/recipient CMV-negative (D+/R-) and 16 CMV-seropositive recipients (R+). CMV-specific CD4+ and CD8+ T cells were quantified by

Aim

assay at 2 weeks and at 3, 6, 9, and 12 months. CS-CMVi was defined as CMV infection requiring antiviral therapy.

Results

Immune reconstitution featured expansion of CD4+ TEMRA and Th1-like cells with contraction of Th2/Th17 subsets. Seven recipients (24%) developed CS-CMVi, including five D+/R-. Early CD4+-predominant CMV-specific responses shifted toward CD8+ expansion with viral replication. At 2 weeks, the CMV-specific CD4+: CD8+ ratio was associated with CS-CMVi (AUC 0.83, p = 0.012); a cut-off ≥1.37 yielded 86% sensitivity and 71% specificity. After 6 months, CMV serostatus shaped Th-cell activation, with R+ recipients showing greater Th1/Treg and reduced Th2/Th17 responsiveness.

Conclusion

Early CMV-specific CD4+/CD8+ imbalances measured by

Aim

are associated with CS-CMVi and reflect distinct trajectories of immune reconstitution after KT. These findings support prospective evaluation of CMV-

Aim

assays as precision immune-monitoring tools in larger studies.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.